These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 27317305

  • 1. Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers.
    Zhang M, Wang ZZ, Ni XJ, Li LZ, Zhang YF, Lu HY, Peng H, Huang WC, Shen LF, Xiong LH, Shang DW, Wen YG.
    Clin Drug Investig; 2016 Sep; 36(9):705-711. PubMed ID: 27317305
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y, Ishibashi T, Fukuyama H, Fukase H, Shimada J.
    Antivir Ther; 2017 Sep; 22(4):313-323. PubMed ID: 27805571
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M, Ni Y, Zhou Y, He X, Li H, Chen H, Li W.
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice.
    Kodama M, Yoshida R, Hasegawa T, Izawa M, Kitano M, Baba K, Noshi T, Seki T, Okazaki K, Tsuji M, Kanazu T, Kamimori H, Homma T, Kobayashi M, Sakoda Y, Kida H, Sato A, Yamano Y.
    Antiviral Res; 2014 Sep; 109():110-5. PubMed ID: 24997412
    [Abstract] [Full Text] [Related]

  • 11. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
    Tan QY, Li HD, Zhu RH, Zhang QZ, Zhang J, Peng WX.
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of cefozopran by single and multiple intravenous infusions in healthy Chinese volunteers.
    Wu GL, Shentu JZ, Zhou HL, Zhu MX, Hu XJ, Liu J, Wu LH.
    Drugs R D; 2015 Mar; 15(1):63-70. PubMed ID: 25644122
    [Abstract] [Full Text] [Related]

  • 13. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
    Bazan JA, Bauer KA, Hollister AS, Shidham G, Firstenberg MS, Reed EE, Mangino JE, Goff DA.
    Pharmacotherapy; 2010 Oct; 30(10):1016-20. PubMed ID: 20874039
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
    Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):369-77. PubMed ID: 22024821
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.
    Liu J, Zhai Y, Wu L, Wu G, Zheng Y, Hu X, Shentu J.
    Drug Des Devel Ther; 2020 Jan; 14():613-620. PubMed ID: 32103903
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.